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Abstract
Background: Fine needle aspiration (FNA) biopsy plays a critical role in the diagnosis and staging of lung primary
and metastatic lung carcinoma. Accurate subclassification of adenocarcinoma (ADC) and/or squamous cell
carcinoma (SqCC) is crucial for the targeted therapy. However, the distinction between ADC and SqCC may be
difficult in small FNA specimens. Here, we have retrospectively evaluated the utility of TTF-1, Napsin A, CK7, P63
and CK5/6 immunohistochemical (IHC) markers in the distinguishing and subclassification of ADC and SqCC.
Methods: A total of 246 FNA cases were identified by a computer search over a two-year period, including 102
primary NSCLC and 144 primary NSCLC which had metastasized to other sites. The immunostaining patterns of
TTF-1, Napsin A, CK7, P63 and CK5/6 were correlated with the histological diagnosis of the tumor.
Results: In 72 primary ADCs, TTF-1, Napsin A and CK7 showed a sensitivity and specificity of 84.5%/96.4%, 92.0%/
100%, and 93.8%/50.0%. In 30 primary SqCCs, CK5/6 and P63 showed a sensitivity and specificity of 100%/77.8%
and 91.7%/78.3%. In 131 metastatic ADCs, Napsin A showed the highest specificity (100%), versus TTF-1 (87.5%)
and CK7 (25%) but decreased sensitivity (67.8% versus 86.9% and 100%); whereas in 13 metastatic SqCCs, CK5/6
and P63 showed a sensitivity/specificity of 100%/84.6% and 100%/68.4%. Bootstrap analysis showed that the
combination of TTF-1/CK7, TTF-1/Napsin A and TTF-1/CK7/Napsin A had a sensitivity/specificity of 0.960/0.732,
0.858/0.934, 0.972/0.733 for primary lung ADCs and 0.992/0.642, 0.878/0.881, 0.993/0.618 for metastatic lung ADCs.
Conclusions: Our study demonstrated that IHC markers had variable sensitivity and specificity in the subclassification
of primary and metastatic ADC and SqCC. Based on morphological findings, an algorithm with the combination use of
markers aided in the subclassification of NSCLCs in difficult cases.
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Background
Lung cancer is the leading cause of cancer-related
mortality, accounting for over 150,000 deaths per year
in the United States and over 1.3 million death world-
wide [1,2]. Primary lung carcinomas have been classified
into small cell lung carcinoma (SCLC) and non-small
cell lung carcinoma (NSCLC). The later include adeno-
carcinoma (50-70%), squamous cell carcinoma (20-30%)
and other subtypes (<10%) [3,4]. Molecular studies of
lung cancers have led to the development of personal-
ized/targeted therapy [5-12]. An important example is
the discovery of epidermal growth factor receptor gene
(EGFR) alterations, and the successful administration of
EGFR tyrosine kinase inhibitors (TKIs) in lung cancer
patients whose tumor harbors EGFR alterations [5,10,13].
Another therapeutic target, the echinoderm microtubule-
associated protein like 4(EML4)-anaplastic lymphoma
kinase (ALK) fusion protein, has also been uniquely de-
tected in a subset of adenocarcinomas [8]. Recently,
more targeted therapies aimed at specific pathways and/
or cell types have been developed and are in clinical trials
[5,7,11]. Taken together, subclassification of NSCLC
plays a critical role in the clinical management of NSCLC
patients [14].
The majority of NSCLC patients present with ad-
vanced and/or metastatic disease [2,3,8]. Fine needle
aspiration (FNA) cytology performed either by trans-
thoracic and/or transbronchial procedures are import-
ant approaches to obtain tumor tissue for histological
diagnosis and molecular characterization of tumors
[15,16]. However FNA specimens are usually small
and contain with a limited amount of tumor. Patholo-
gists, therefore, have been faced with the challenge of
an increased volume of specimens along with a con-
current demand for precise subclassification of lung
cancers. For FNA specimens, the distinction between
adenocarcinoma (ADC) and squamous cell carcinoma
(SqCC) can be challenging due to scant tumor tissue
[16-19] and several other factors, such as an obscuring
tumor diathesis, crushing and drying preparation arti-
facts [19-21]. As a result, immunohistochemistry (IHC)
has been increasingly used to aid in the subclassifica-
tion of NSCLC [19-23].
Numerous recent studies have been published to ad-
dress the utility of IHC markers in the diagnosis and sub-
classification of NSCLC using surgically resected tumor
tissue [20,21,24] as well as FNA specimens [19-23,25].
However, the clinical question of how to construct an
IHC panel with limited number of IHC markers and par-
ticularly how to apply commonly used IHC markers in
FNA cases is still under debate. Furthermore, a daily
challenge in clinical practice involves how to best use a
minimal amount of tumor tissue while making an accur-
ate and rapid diagnosis.
In this study, we have retrospectively studied five most
commonly used IHC markers, TTF-1, Napsin A, CK7,
P63 and CK5/6 in the subclassification of NSCLC using
cytological FNA cases. We have included both primary
NSCLCs and tumors of primary NSCLC which had me-
tastasized to other body sites, and compared the sensi-
tivity and specificity of these markers individually and in
combinations. The purpose of our study is to evaluate
our institutional experience and to provide an evidence-




The cytological archive of the Department of Pathology
at the Johns Hopkins Hospitals was searched using
Boolean terms “NSCLC or ADC or SqCC” and “IHC
markers”, including TTF-1, Napsin A, CK7, P63 and
CK5/6 based on a period of 24 months (from 2010 to
2011). The search yielded 246 FNA cases, including 102
cases of primary lung ADC and SqCC, and 144 meta-
static cases of primary lung ADC and SqCC to other
sites. The available slides and the clinical information
were reviewed and correlated. The study was approved
by the Johns Hopkins Institutional Review Board (IRB).
All study cases were annotated with available clinical
information in a manner that protected patient privacy.
Immunohistochemistry (IHC)
All of the IHC stains were performed at our clinical im-
munohistochemistry laboratory as previously described
[22]. Briefly, the specimens were sectioned at 5 μm,
deparaffinized and incubated with primary antibodies.
Information of primary antibodies were summarized
in the Table 1. Napsin A was stained using the Leica
Bondmax autostainer (Leica, Buffalo, IL). TTF-1, CK7,
CK5/6 and P63 were stained using the Ventana XT
autostainer. Staining characteristics were reviewed and
considered along with the intensity and distribution of
staining patterns. A case was considered to be positive
if greater than 5% of tumor cells with an appropriate
staining pattern were identified; otherwise the case
was considered to be negative. In terms of specific
staining patterns, coarse granular cytoplasmic staining
was considered positive for Napsin A. Nuclear staining
was considered positive for TTF-1 and P63. Cytoplas-
mic staining was considered positive for CK7 and
CK5/6. Appropriate positive and negative controls
were included in each assay. Care was taken not to in-
terpret entrapped normal lung bronchial epithelium or
pulmonary macrophages as a positive staining.
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Statistical analysis
The characteristics of IHC markers were compared be-
tween different groups, including primary lung carcin-
omas and lung primary carcinomas metastatic to other
sites. Any missing values due to loss of tumor tissue on
cell blocks or if IHC was not performed were elimi-
nated from the statistical analysis. Both individual and
combinations of IHC stains were assessed to differenti-
ate between primary and metastatic tumors. Statistical
analysis was performed using GraphPad Prism software
(GraphPad software Inc, La Jolla, CA). The bootstrap
analysis (with 1000X re-sampling of the dataset) was also
used to analyze the sensitivity and specificity for the com-
bination of individual markers [26]. A P value equal
and/or less than 0.05 (P ≤ 0.05) was considered as statisti-
cally significant. The sensitivity, specificity, positive pre-
dictive value (PPV) and negative predictive value (NPV)
were calculated based on the final cytological diagnosis.
Results and discussion
Clinical information
Recent advances in the targeted therapy of lung cancers
require an accurate subclassification of NSCLC. FNA-
based cytological diagnosis is often the crucial first step
in the diagnosis of a lung mass [7,16,18]. FNA specimens
have unique problems, including small amount of tumor
cells within the specimen, and potential specimen prep-
aration artifacts. These features could affect the diagnosis
and subclassification of NSCLC, so it may be difficult to
subclassify the tumor by using routine hematoxylin and
eosin (H & E) stained sections. Therefore, IHC markers
are frequently used to aid in the diagnosis. Recent publi-
cations have already addressed the issue in the subclas-
sification of NSCLC via small tissue biopsies and the
utility of IHC markers in the surgical pathology setting
[24,27-29]. However, evidence-based studies are still ne-
cessary for the determination of the optimal utilization
of IHC markers, particularly in FNA specimens. In this
study, we have retrospectively studied five most com-
monly used IHC markers, including TTF-1, Napsin A,
CK7, P63 and CK5/6 in the subclassification of NSCLC
in a large cohort (n = 246 cases) of cytological FNA cases.
Of 246 FNA cases, 102 cases were primary NSCLC, in-
cluding 72 ADCs and 30 SqCCs, and 144 cases were
primary NSCLC metastases to other body sites. Of meta-
static NSCLCs, there were 131 ADCs and 13 SqCCs. The
patient clinical characteristics were summarized in the
Table 2. There were no gender and age differences be-
tween the primary and metastatic NSCLC (P = 0.3638 and
P = 0.4110, respectively). All cases of primary NSCLCs
had a clinical presentation of lung masses and radio-
graphic diagnosis/suspicion of lung carcinomas, and 38%
of the cases (39/102) had subsequent surgical biopsy and/
or resection. In metastatic cases, 47.2% of cases (68/144)
had a history of NSCLCs. The location of metastatic tu-
mors is summarized in the Table 3. The most frequent
metastatic body sites were local lymph nodes (45.14%,
65/144 cases) and pleural cavity (29.86%, 43/144 cases),
respectively.
From our experience, most small biopsies lung cancer
cases can be classified based on morphological evalu-
ation, while about 30% to 40% of cases need IHC study
in order to accurately classify the tumor, particularly in
metastatic carcinomas. The clinical separation of the
two major subtypes (ADC vs SqCC) has significant im-
pact on the targeted therapy. Thus, in this study we
have focused on the evaluation of the clinical utility of
five most commonly used IHC markers in the subclas-
sification of ADC and SqCC.
Table 1 Summary of primary antibody information
Antibody Source Clonality Clone Species Dilution Pretreatment
TTF-1 Ventana Monoclonal 8G7G3/1 Mouse Prediluted CC1
Napsin A Novocastra Monoclonal IP64 Mouse 1:800 Bond enzyme
CK7 Dako Monoclonal Ov-tl Mouse 1:500 None
P63 BioCare Monoclonal 4a4 Mouse Prediluted CC1
CK5/6 Ventana Monoclonal D5/16 B4 Mouse Prediluted CC1
CC1: cell conditioning 1.






Sex* (cases (%)) 0.3638
Male 46 (45.5%) 75 (52.1%)
Female 55 (54.5%) 69 (47.9%)
Age (years) 0.4110
Average ± SD 65.0 ± 11.2 63.8 ± 11.3
Median 67.0 64.0
Range 29-85 32-89
Adenocarcinomas 72 (70.6%) 131 (91.0%) N/A
Squamous cell carcinomas 30 (29.4%) 13 (9.0%)
Total cases 102 144 N/A
FNA: find needle aspiration. *For one case of a primary lung tumor, the patient
sex was unknown.
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Individual staining patterns of CK5/6 and P63 in SqCCs
The cytological features of SqCCs include pleomorphic
large tumor cells with hyperchromatic nuclei, opaque
or “hard” cytoplasm, intracytoplasmic processes, or
other features characteristic of squamous differenti-
ation (Figure 1). Immunostaining patterns of P63 and
CK5/6 in SqCCs are shown in Figure 1 and Table 4.
CK5/6 showed 100% positivity in both primary and
metastatic tumors, whereas, P63 showed a 91.7% and
100% positivity in primary and metastatic tumors, re-
spectively (Table 4). The sensitivity, specificity, positive
predictive value (PPV) and negative predictive value
(NPV) of CK5/6 and P63 in primary and metastatic SqCC
are summarized in Table 5. In primary SqCCs, CK5/6
showed a slightly higher sensitivity than P63 (100% vs
91.7%), and similar specificity as P63 (77.8% vs 78.3%).
In metastatic SqCCs, both CK5/6 and P63 revealed to
have the same sensitivity (100% vs 100%), but CK5/6
showed a higher specificity than that of P63 (84.6% vs
68.4%, P < 0.05).
In SqCCs, we also found that TTF-1 and Napsin A
could stain entrapped bronchial epithelial cells (Figure 1D)
and alveolar macrophages (data not shown) rather than
tumor cells. In this circumstance, tumor cells were consid-
ered negative for TTF-1 and Napsin A.
In SqCCs, P63 and CK5/6 are commonly used markers.
Human TP63 gene is located on the chromosome 3q27-
29; and the expression of the gene produces the full-
length protein P63 and the truncated protein P40 [22,24].
P63 can be detected in benign bronchial stem cells and in
neoplastic cells with evidence of squamous differenti-
ation [30]. CK5/6 is a high molecular weight cytokeratin
and expressed in neoplasms of epithelial origin, including
SqCC, mesothelial carcinoma and urothelial carcinoma
Table 3 Locations of metastatic tumors of the lung
Sites of Metastatic NSCLC Cases (Percentage)
Adenocarcinoma (n = 131)
Lymph node 59 (45.0%)
Pleural fluid 40 (30.5%)
Soft tissue 8 (6.1%)
Bone 7 (5.3%)
Liver 6 (4.6%)
Pericardial fluid 4 (3.1%)
Peritoneal fluid 3 (2.3%)
Other organs 4 (3.1%)
Squamous cell carcinoma (n = 13)
Lymph node 6 (46.2%)
Pleural fluid 3 (23.1%)
Soft tissues 3 (23.1%)
Other organs 1 (7.7%)
Figure 1 Immunostaining pattern of CK5/6 and P63 in squamous cell carcinomas. A, histomorphology of SqCC on H&E slide; B, immunostain of
CK5/6 in tumor cells, C, immunostain of P63 in tumor cells, and D, stain of TTF-1 in tumor cells and entrapped normal lung bronchial epithelium.
Tumor cells of SqCC are positive for CK5/6 and P63, but negative for TTF1.
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[31]. P63 and CK5/6 have been used in the diagnosis of
lung SqCC [23,24,27,32], however typically in much
smaller cohorts (≤50 cases) [23,32] than our study here.
Our data demonstrates that P63 and CK5/6 have the sen-
sitivity and specificity of 91.7% and 78.3%, and 100% and
77.8%, respectively. We found that CK5/6 to be more sen-
sitive in primary SqCC, and more specific for metastatic
SqCC (Tables 3 and 4). Both of these markers however
can be detected in subset of ADCs. For example, P63 ex-
pression can be seen in 21.7% of primary ADCs and
31.6% of metastatic ADCs (Table 4). However it usually
shows weak and focal expression in contrast to strong
and diffuse staining seen in SqCC. These observations
arise the potential possibility of glandular differentiation
in SqCC. It has also been reported that in cases of poorly
differentiated ADCs, which show a decreased expression
of Napsin A and TTF-1 [19,21], and a proportion of these
tumors have been shown to be P63-positive [33,34]. Simi-
larly, CK5/6 has also been detected in a subset of primary
ADCs (22.2%) and metastatic ADCs (15.4%). In addition,
CK5/6 has also been detected in some cases of pancreatic,
endometrial and breast ADCs [31].
ΔNP63 (N-terminal-truncated protein isoform of
TA63), the truncated form of P63 without the transac-
tivation domain, can be identified by the antibody
designated as P40. P40 has been reported to have bet-
ter sensitivity and specificity than P63 in the identifica-
tion of SqCCs. Our previous study, however, showed
that in SqCC P40, P63 and CK5/6 had a sensitivity of
80.5%, 90.0% and 93.5% and a specificity of 80.0%,
89.6% and 80.0%, respectively [21].
In addition, we also found that CK7 was positive in
50% (7/14 cases) of primary SqCCs and 75% (3/4 cases)
of metastatic SqCCs. However, our study only had few
cases of SqCC. A further study with larger numbers is
necessary to draw a conclusion.
Staining patterns of TTF-1, Napsin A and CK7 in ADCs
The cytological features of ADCs include clusters of
tumor cells with prominent nucleoli, predominate or
overt mucin production, vacuolated cytoplasm, acinar
formation and other features characteristic of glandu-
lar differentiation (Figure 2). Immunostaining patterns
of TTF-1, Napsin A, and CK7 in ADCs are shown in
Figure 2 and Table 4. TTF-1 showed 84.5% and 86.9%
positivity in primary and metastatic ADCs, whereas,
Napsin A showed 92% and 67.8% positivity in primary
and metastatic ADC, and CK7 showed 93.8% and 100%
positivity in primary and metastatic ADCs, respectively,
(Table 4). The sensitivity, specificity, PPV and NPV of
Table 4 Immunostaining patterns in primary and metastatic NSCLC
NSCLC P63 CK5/6 Napsin A TTF-1 CK7
Positive/total Positive/total Positive/total Positive/total Positive/total
(%) (%) (%) (%) (%)
Primary lung carcinomas (n = 102)
ADC (n = 72) 5/23 2/9 23/25 60/71 45/48
(21.7%) (22.2%) (92.0%) (84.5%) (93.8%)
SqCC (n = 30) 22/24 18/18 0/8 1/28 7/14
(91.7%) (100.0%) (0.0%) (3.6%) (50.0%)
Metastatic tumor of the lung (n = 143)
ADC (n = 131) 6/19 2/13 40/59 113/130 101/101
(31.6%) (15.4%) (67.8%) (86.9%) (100.0%)
SqCC (n = 13) 11/11 6/6 0/3 1/8 3/4
(100.0%) (100.0%) (0.0%) (12.5%) (75.0%)
NSCLC: non-small cell lung carcinoma. ADC: adenocarcinoma. SqCC: squamous cell carcinoma.
Table 5 Performance of individual marker in primary and metastatic lung squamous cell carcinomas
Type Primary SqCC (n = 30) vs Metastatic SqCC (n = 13) vs
Primary ADC (n = 72) Metastatic ADC (n = 131)
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
P63 91.7% 78.3% 81.5% 90.0% 100.0% 68.4% 64.7% 100.0%
CK5/6 100.0% 77.8% 90.0% 100.0% 100.0% 84.6% 75.0% 100.0%
ADC: adenocarcinoma. SqCC: squamous cell carcinoma. PPV: positive predictive value. NPV: negative predictive value.
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TTF-1, Napsin A and CK7 in primary and metastatic
ADC are summarized in Table 6. TTF-1 showed similar
sensitivity between primary and metastatic ADCs (84.5%
vs 86.9%, P > 0.05), but a higher specificity in primary
ADCs than metastatic ADCs (96.4% vs 87.5%, P < 0.05).
Napsin A showed a higher sensitivity in primary ADC
than that of metastatic ADCs (92.0% vs 67.8%, P < 0.05),
and the same specificity in both primary and metastatic
ADC (100% for both). The sensitivity and specificity of
CK7 in primary and metastatic ADCs were 93.8% and
50%, and 100% and 25%. In addition to ADCs, we also
found that CK7 showed 50% and 75% positivity in pri-
mary and metastatic SqCC, respectively. Taken together,
TTF-1 had a better sensitivity, and Napsin A had a better
specificity for the primary lung ADCs. Whereas, CK7
showed a suboptimal specificity for lung ADCs.
CK7, TTF-1 and Napsin A are the most commonly
used primary lung ADC markers in daily practice. Al-
though CK7 has been used for decades to identify lung
ADCs, its suboptimal sensitivity and specificity are well-
known [24,27,35]. TTF-1 is a nuclear transcript factor
that is expressed in epithelial cells of the lung and thy-
roid. In the lung, it regulates the expression of genes
involved in production of surfactant. The sensitivity and
specificity of TTF-1 in the identification of lung origin vary,
and range from 75% to over 95% [23,27,28,36]. However,
TTF-1 is also immunoreactive in several other tumors, such
as thyroid neoplasms, breast adenocarcinoma, gastro-
intestinal carcinomas, small cell lung carcinoma (SCLC),
carcinoid and, possibly but controversially [37], primary
lung squamous cell carcinoma [35,38-43]. Napsin A is a
relatively new marker for primary lung ADCs [44]. It is a
Figure 2 Immunostaining pattern of TTF-1, Napsin A and CK7 in adenocarcinomas. A, histomorphology of ADC on H&E slide; B, immunostain of
TTF-1 in tumor cells, C, immunostain of Napsin A in tumor cells, D, stain of CK7 in tumor cells, E, stain of P63 in tumor cells, and F, stain of CK5/6
in tumor cells. Tumor cells of ADC are positive for TTF-1, Napsin A and CK7, but negative for P63 and CK5/6.
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35-kilodalton protein that is expressed in type II pneu-
mocytes, alveolar macrophages, and renal tubular cells
[44]. Functionally, it is an aspartic protease involved in
the posttranslational modification of surfactant protein B
(SP-B) in type II pneumocytes [45]. The expression of
Napsin A has been shown to be transcriptionally regu-
lated by TTF-1 [46]. Previous studies using surgical
resected specimens indicated that Napsin A has a better
sensitivity and specificity than TTF-1 in well to moder-
ately differentiated lung ADCs [22,23,43]. Therefore, it
has been used with TTF-1 together in the differential
diagnosis of lung adenocarcinomas [23,47]. Napsin A
may be particularly useful in poorly differentiated ADCs,
which may lose TTF-1 expression [16,19].
In our study, CK7 has a sensitivity and specificity of
93.8% and 50.0% in primary lung ADCs, and 100% and
25.0% in metastatic lung ADCs. TTF-1 has the sensitiv-
ity and specificity of 84.5% and 96.4% in primary lung
ADCs, and 86.9% and 87.5% in metastatic lung ADCs.
Napsin A has sensitivity and specificity of 92.0% and
100% in the primary lung ADCs, and 67.8% and 100%
in metastatic lung ADCs. Taken together, all three
markers revealed similar sensitivities in primary lung
ADCs; Napsin A showed the best and CK7 showed the
worst specificity. In metastatic ADCs, CK7 showed
better sensitivity than TTF-1 and Napsin A, but the
worst specificity. In our medical institutions, Napsin A
was introduced to the clinical practice in 2008. Interest-
ingly, we found that the addition of Napsin A to routine
practice coincided with an increase in the diagnosis of
ADC subtypes from 14% to 36% and a concurrent decrease
in NOS (otherwise not further classified) subtypes from
24% to 9% among NSCLC. This observation of improved
subclassification of NSCLC with the use of Napsin A has
also been reported elsewhere [22,23,36,48]. All studies,
however, should also address limitations of Napsin A in-
cluding: (a) Napsin A is positive in some cases of SCLC
and lung carcinoid [42], (b) Napsin A is positive in some
cases of renal cell carcinomas [43] and (c) Napsin A also
stains pulmonary macrophages [37], which need to be
distinguished morphologically from tumor cells. With
these caveats in mind, we show that Napsin A exhibits
strong specificity for ADCs of the lung origin.
The combination of IHC markers in NSCLCs
We also examined the utility of these IHC markers in
combinations. In SqCCs, we found that 14 cases of pri-
mary and 3 cases of metastatic tumors had both CK5/6
and P63 staining. Of SqCCs with paired IHC, we found
that two P63 negative SqCCs were positive for CK5/6,
and one CK5/6 negative SqCC was positive for P63. In
primary ADCs, we found that 24 cases were stained with
TTF-1 and Napsin A, 31 cases were stained with TTF-1
and CK7, and 14 cases were stained with TTF-1, Napsin
A and CK7. In metastatic ADCs, we found that 9 cases
were stained with TTF-1 and Napsin A, 52 cases were
stained with TTF-1 and CK7, and 49 cases were stained
with TTF-1, Napsin A and CK7. Of cases with paired
IHC, six Napsin A negative cases were positive for
TTF1, and two TTF-1 negative cases were positive for
Napsin A.
To further test the sensitivity and specificity of IHC
markers in combination, we used the bootstrap resam-
pling approach to analyze both primary and metastatic
NSCLCs. In ADCs, the utility of a combination of IHC
markers (TTF-1, Napsin A and CK7) was compared
with individual markers, with the results of primary
ADCs shown in Figure 3, and metastatic ADCs shown
in Figure 4. The sensitivity and specificity of combined
markers were summarized in Table 7. Taken together, in-
clusion of TTF-1 and/or Napsin A in a panel shows an im-
proved specificity in both primary and metastatic ADCs.
In SqCCs, the utility of combinations of IHC
markers P63 and CK5/6 was compared with individual
markers, and results of primary SqCCs are shown in
Figure 5 and metastatic SqCCs are shown in Figure 6.
The sensitivity and specificity of combined markers
were summarized in Table 8. Although the specificity
of P63 and CK5/6 is similar in primary SqCCs, CK5/6
shows better specificity in metastatic SqCCs.
The bootstrap method is a computer simulation
technique based on random re-sampling of a dataset
and subsequent analysis of the data distribution [26]. It
is commonly used to estimate confidence intervals, the
bias and variance of the actual dataset. Our data dem-
onstrated that the combination of TTF-1 and Napsin A
showed the highest specificity among three different
Table 6 Performance of individual marker in primary and metastatic lung adenocarcinomas
Type Primary ADC (n = 72) vs Metastatic ADC (n = 131) vs
Primary SqCC(n = 30) Metastatic SqCC(n = 13)
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
TTF-1 84.5% 96.4% 98.4% 71.1% 86.9% 87.5% 99.1% 29.2%
CK7 93.8% 50.0% 86.5% 70.0% 100.0% 25.0% 97.1% 100.0%
Napsin A 92.0% 100.0% 100.0% 80.0% 67.8% 100.0% 100.0%% 13.6%
ADC: adenocarcinoma. SqCC: squamous cell carcinoma. PPV: positive predictive value. NPV: negative predictive value.
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combinations of TTF-1 + CK7, TTF1 + Napsin A and
TTF-1 + CK7 + Napsin A in the identification of both
primary and metastatic lung ADCs (Table 7). The spe-
cificity of P63 and CK5/6 is similar in primary SqCCs,
CK5/6 shows better specificity in metastatic SqCCs
(Table 8).
Based on the findings that TTF-1 and Napsin A have a
high sensitivity and specificity for the diagnosis of pri-
mary lung ADCs, and CK5/6 stain is highly sensitive
and specific for squamous differentiation, we outlined an
algorithmic approach in the subclassification of NSCLC
using FNA cases (Figure 7). In the algorithm, the
Figure 3 The sensitivity and specificity of IHC markers, as individual or in combination, in primary lung adenocarcinomas by the bootstrap
resampling analysis.
Figure 4 The sensitivity and specificity of IHC markers, as individual or in combination, in metastatic lung adenocarcinomas by the bootstrap
resampling analysis.
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Table 7 Performance of markers in primary and metastatic lung adenocarcinomas by bootstrap analysis
Markers Sensitivity Specificity
Average ± SD Range Average ± SD Range
Primary ADCs
TTF-1 0.848 ± 0.0446 0.690 – 0.972 0.934 ± 0.0438 0.800 – 1.000
Napsin A 0.919 ± 0.0545 0.720 – 1.000 1.000 ± 0.0000 1.000 – 1.000
CK7 0.941 ± 0.0330 0.833 – 1.000 0.489 ± 0.1432 0.077 – 0.769
TTF-1 + CK7 0.960 ± 0.0231 0.718 – 0.986 0.732 ± 0.0919 0.533 – 0.967
TTF-1 + Napsin 0.858 ± 0.0420 0.875 – 1.000 0.934 ± 0.0417 0.833 – 1.000
TTF-1 + CK7 + Napsin A 0.972 ± 0.0197 0.887 – 1.000 0.737 ± 0.0850 0.500 – 0.900
Metastatic ADCs
TTF-1 0.870 ± 0.0310 0.808 – 0.946 0.870 ± 0.1243 0.500 – 1.000
Napsin A 0.702 ± 0.0647 0.559 – 0.881 1.000 ± 0.0000 1.000 – 1.000
CK7 1.000 ± 0.0000 1.000 – 1.000 0.285 ± 0.2358 0.000 – 1.000
TTF-1 + CK7 0.992 ± 0.0086 0.969 – 1.000 0.624 ± 0.1662 0.125 – 1.000
TTF-1 + Napsin 0.878 ± 0.0298 0.794 – 0.939 0.881 ± 0.1286 0.375 – 1.000
TTF-1 + CK7 + Napsin A 0.993 ± 0.0072 0.969 – 1.000 0.618 ± 0.1793 0.125 – 1.000
ADC: adenocarcinoma. SqCC: squamous cell carcinoma.
Figure 5 The sensitivity and specificity of IHC markers, as individual or in combination, in primary lung squamous cell carcinomas by the
bootstrap resampling analysis.
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evaluation of cytological morphology in the conjunction
of immunostaining patterns is necessary for the final
diagnosis of the tumor and/or further decision-making
steps. For example: (a) ADCs should be favored for
cases with both Napsin A and TTF-1 positivity;
alternatively, either TTF-1 or Napsin A positivity,
alongside CK5/6 negativity, (b) SqCCs should be fa-
vored for cases with CK5/6 positivity alongside Napsin
A and TTF-1 negativity. The use of CK7 and P63 was
not necessary to improve the identification of either
Figure 6 The sensitivity and specificity of IHC markers, as individual or in combination, in metastatic squamous cell carcinomas by the bootstrap
resampling analysis.
Table 8 Performance of marker in primary and metastatic lung squamous cell carcinomas by bootstrap analysis
Markers Sensitivity Specificity
Average ± SD Range Average ± SD Range
Primary SqCCs
P63 0.921 ± 0.0557 0.750 – 1.000 0.780 ± 0.0913 0.522 – 0.957
CK5/6 1.000 ± 0.0000 1.000 – 1.000 0.769 ± 0.1410 0.333 – 1.000
P63 + CK5/6 1.000 ± 0.0000 1.000 – 1.000 0.766 ± 0.0872 0.480 – 0.920
Metastatic SqCCs
P63 1.000 ± 0.0000 1.000 – 1.000 0.691 ± 0.1068 0.421 – 0.947
CK5/6 1.000 ± 0.0000 1.000 – 1.000 0.839 ± 0.1009 0.615 – 1.000
P63 + CK5/6 1.000 ± 0.0000 1.000 – 1.000 0.716 ± 0.0901 0.500 – 0.857
ADC: adenocarcinoma. SqCC: squamous cell carcinoma.
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ADC or SqCC. However, in poorly differentiated
NSCLCs and/or adenosquamous carcinomas more IHC
markers are needed. This approach may potentially im-
prove the detection specificity, and may prove to be of
diagnostic significance, as patients with poorly differen-
tiated carcinomas may benefit from molecular screening
for EGFR, KRAS or ALK mutations. As a note of cau-
tion, additional IHC markers are necessary to identify
the origin of the tumor in cases of non-pulmonary car-
cinomas metastatic to the lung, and a careful clinical
evaluation in these settings is also necessary [49]. The
study by Su YC, et al., reported that CK7 was frequently
detected in breast carcinoma in addition to lung ADCs,
and CK20 was significantly more frequently detected in
gastrointestinal carcinomas [50]. The other study by
Kargi A, et al., reported that a subset of SCLC had a
positive immunostaining pattern of TTF1 and negative
immunostaining pattern of P63 [51]. Therefore, the in-
terpretation of IHC patterns should be correlated with
the morphological findings.
Conclusions
The 2011 IASLC/ATS/ERS lung adenocarcinoma classi-
fication recommends using a single adenocarcinoma
marker (TTF-1 or Napsin A) and a single squamous
marker for NSCLC classification in small biopsy or
cytology specimen in the absence of definitive glandular
or squamous morphology to reserve tissue [3]. Our cohort
showed that TTF-1 and Napsin A tend to have variable
sensitivity and specificity in primary and metastatic adeno-
carcinoma of the lung. In metastatic adenocarcinoma, the
lower sensitivity of Napsin A may lead to an inappropriate
exclusion of patients from receiving the benefits of tar-
geted therapy. Therefore combined use of TTF-1, Napsin
A and CK7 could be considered in problematic cases.
In summary, the FNA-based sampling could present
a unique set of diagnostic challenges, such as small
amount of tumor cells, obscuring effect of tumor ne-
crosis, the need to assess samples from different areas/
multiple needle passes on a single slide and difficulty in
quantifying the degree or extent of IHC staining. We
evaluated the most commonly used five IHC markers,
including TTF-1, Napsin A, CK7, P63 and CK5/6 in
the subclassification of NSCLC. Based on our findings,
we propose an algorithmic approach utilizing a panel of
IHC markers for subclassification of NSCLC. Our step-
wise approach allows prioritization of markers if the
amount of tissue or resources is limited, in order to
optimally conserve tissue for future molecular testing
of the lung carcinoma. This subclassification approach
has the potential benefit to improve the IHC diagnostic
utilization. A further prospective study using independently
collected cohort is necessary to validate our approach.
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